Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Artios completes £65m Series B investment round

10 Aug 2018 07:00

Arix Bioscience Plc - Artios completes £65m Series B investment round

Arix Bioscience Plc - Artios completes £65m Series B investment round

PR Newswire

London, August 10

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014

Arix Bioscience plc

Artios completes £65m Series B investment round

 Arix interest increased to £15.3 million ($19.7 million1), becoming largest shareholder in Artios

Supporting proven management team in accelerating development of next generation DNA Damage Response (DDR) pipeline

LONDON, 10 August, 2018: Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today announces that its Group Business Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, has completed an oversubscribed £65 million ($84 million1) Series B financing (the “Financing”) following strong interest from investors.

As part of the Financing, Arix:

Committed to invest £8 million ($10.3 million[1]) over two tranches;

Completed its remaining £1.5 million ($1.9 million1) Series A commitment; and

Invested a further £0.6 million ($0.8 million1) by purchasing a stake from an existing shareholder.

Following this investment, Arix becomes the largest shareholder in Artios, retaining a 12.4% stake on a fully diluted basis. Arix’s Jonathan Tobin will continue to serve on the Artios Board.

The financing recognised a 26% uplift in the book value of Arix’s Series A investment in Artios, with Arix’s total interest in Artios increasing to £15.3 million from £5.1 million.

The new funds will enable Artios to advance its portfolio of first-in-class, small molecule DDR programmes, including its lead programme targeting DNA polymerase theta (Pol?), through clinical proof of concept trials.

New global institutional investors Andera Partners, Life Sciences Partners, Pfizer Ventures and Novartis Venture Fund joined the Series B round. In addition to Arix, Artios’ existing shareholders SV Health Investors, M Ventures, IP Group plc and AbbVie Ventures also participated in the round.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: “Artios is actively developing a pipeline of highly promising, first-in-class DDR therapies which have the potential to bring real impact to cancer patients. We are delighted to support this proven management team, which during their tenure at KuDOS (successfully sold to AstraZeneca) played a key role in the discovery and early development of olaparib, the first approved DDR therapy and PARP inhibitor, now used to treat ovarian and breast cancer, creating a billion dollar market. As early investors in Artios, we are excited to continue working with the team and this group of renowned investors to build a world leading DDR company and create significant value for both patients and investors.”

Niall Martin, Chief Executive Officer of Artios added:Arix is focused on supporting innovation and creating and building world class companies. They were instrumental in putting together this stellar investor syndicate and we value their continued support as we progress the development of our novel DDR programmes.”

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Hollie Vile

+44 203 714 1787

optimum.arix@optimumcomms.com

Burns McClellan (US Media & IR Enquiries)

Lisa Burns, John Grimaldi, Bill Slattery Jr., Nancie Steinberg

+1 212-213-0006

arix@burnsmc.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

About Artios Pharma Limited

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as the National Centre for Biomolecular Research at Masaryk University. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. Backed by blue chip investors including: Arix Bioscience plc - the largest shareholder in Artios, SV Health Investors, M Ventures, IP Group plc, AbbVie Ventures, Andera Partners (formerly EdRIP), LSP (Life Science Partners), Pfizer Ventures and Novartis Venture Fund (NVF). Artios is based at the Babraham Research Campus in Cambridge, UK. www.artiospharma.com

[1] At exchange rate on 9 August 2018

Date   Source Headline
3rd Dec 20187:00 amPRNAutolus announces update on AUTO4 and AUTO5 programmes
15th Nov 20187:00 amPRNPositive Phase 1 clinical trial results
12th Nov 20187:00 amPRNArix invests in $70m Harpoon Series C investment round
2nd Nov 201811:33 amPRNAutolus Therapeutics to Present New Data at the ASH
30th Oct 20182:11 pmPRNAura Biosciences reports positive Phase 1b/2 data
24th Oct 20187:00 amPRNLogicBio announces closing of initial public offering
19th Oct 20187:00 amPRNLogicBio prices Nasdaq IPO
10th Oct 20187:00 amPRNUpdate on LogicBio proposed IPO in the United States
1st Oct 20187:00 amPRNCo-leads $58 million Series A for VelosBio
26th Sep 20187:00 amPRNLogicBio files registration for proposed IPO in the US
18th Sep 20182:00 pmPRNUpdate on Iterum Therapeutics Phase 3 trials
12th Sep 20184:30 pmPRNAnnounces Board Changes
10th Sep 20184:24 pmPRNHolding(s) in Company
4th Sep 20187:00 amPRNChanges announced to executive team
17th Aug 20181:01 pmPRNHoldings in Company and Lock-in Agreement
10th Aug 20187:01 amPRNPositive clinical progression in Group Businesses
10th Aug 20187:00 amPRNArtios completes £65m Series B investment round
6th Aug 20187:00 amPRNArix Bioscience announces first VIPE investment
30th Jul 20187:00 amPRNInterim Results for the Six Months Ended 30 June 2018
25th Jul 20184:41 pmPRNNotice of Results
2nd Jul 20181:16 pmPRNTotal Voting Rights
26th Jun 20185:30 pmPRNAutolus annouces closing of IPO
22nd Jun 20187:07 amPRNAutolus Announces Pricing of Initial Public Offering
21st Jun 201810:22 amPRNIssue of Shares, Total Voting Rights & PDMR Notification
11th Jun 20184:23 pmPRNDirector/PDMR Shareholding
8th Jun 201811:36 amPRNUpdate on Autolus proposed NASDAQ IPO
31st May 20182:00 pmPRNLord John Hutton steps down from Board of Directors
30th May 20184:13 pmPRNIterum Therapeutics plc Closes Initial Public Offering
25th May 20187:19 amPRNIterum Therapeutics plc Prices Initial Public Offering
17th May 201812:29 pmRNSResult of AGM
17th May 20187:00 amRNSUpdate on Iterum proposed NASDAQ IPO
8th May 20187:00 amRNSAutolus Files for Proposed US IPO
2nd May 201810:10 amRNSArix notes Iterum?s proposed US IPO
23rd Apr 20187:00 amRNSAnnual Results 2017
16th Apr 20187:25 amRNSNotice of Annual Results
5th Apr 20187:00 amRNSArix to present at HC Wainwright on 10 April
4th Apr 20189:01 amRNSHolding(s) in Company
4th Apr 20189:00 amRNSTotal Voting Rights
26th Mar 20181:40 pmRNSHolding(s) in Company
26th Mar 201812:31 pmRNSArix notes positive Ph2b COPD data from Verona
23rd Mar 20189:00 amRNSHolding(s) in Company
22nd Mar 201811:51 amRNSHolding(s) in Company
21st Mar 201812:46 pmRNSHoldings in Company
21st Mar 201811:40 amRNSDirector/PDMR Shareholding
21st Mar 201811:39 amRNSHolding(s) in Company
16th Mar 201811:45 amRNSResults of General Meeting
16th Mar 20187:00 amRNSResults of Capital Raising
6th Mar 20187:00 amRNSArix notes Autolus's potential US IPO
28th Feb 201811:29 amRNSPublication of a Prospectus
28th Feb 20187:00 amRNSProposed Firm Placing, Placing and Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.